3078 studies found for:    Open Studies | "Carcinoma"
Show Display Options
Rank Status Study
21 Recruiting Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Conditions: Merkel Cell Carcinoma;   Skin Cancer
Intervention: Drug: Cabozantinib
22 Recruiting A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Intervention: Biological: GLA-SE
23 Not yet recruiting A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
Conditions: Advanced Adult Hepatocellular Carcinoma;   Advanced Fibrolamellar Carcinoma
Intervention: Drug: ENMD-2076
24 Recruiting the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma
Conditions: Stage I Hepatocellular Carcinoma;   Stage II Hepatocellular Carcinoma
Interventions: Drug: the ginsenoside Rg3;   Drug: Placebo
25 Recruiting Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With 3 mg/kg BW Ipilimumab (Yervoy®) Versus Observation
Condition: Merkel Cell Carcinoma
Intervention: Drug: Ipilimumab
26 Recruiting F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Interventions: Drug: Arm A: F16IL2 in combination with paclitaxel;   Drug: Arm B: Paclitaxel
27 Unknown  Environmental, Metabolic and Nutritional Factors of Hepatocellular Carcinoma in Cirrhotic Patients
Conditions: Cirrhosis With Hepatocellular Carcinoma;   Cirrhosis Without Hepatocellular Carcinoma
Interventions: Biological: Serum, plasma and DNA samples;   Procedure: Radiological exploration by CT scan or MRI
28 Not yet recruiting Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study
Conditions: Poorly Differentiated Neuroendocrine Carcinoma,;   Neuroendocrine Carcinoma, Grade 3;   Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3;   Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3;   Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)
Intervention: Drug: Everolimus (Afinitor®)
29 Recruiting Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus
Conditions: Clear-cell Renal Carcinoma;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Everolimus
30 Recruiting First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Conditions: Transitional Cell Carcinoma;   Bladder Carcinoma;   Urothelial Carcinoma
Interventions: Drug: Everolimus;   Drug: Paclitaxel
31 Recruiting Chemoradiation for Bladder Preservation in Patients With Muscle Invasive Bladder Carcinoma After Complete Response to Neoadjuvant Chemotherapy
Conditions: Bladder Cancer;   Bladder Carcinoma;   Transition Cell Cancer;   Muscle Invasive Bladder Carcinoma
Interventions: Procedure: Transurethral Resection of the Bladder Tumor & Cystoscopy;   Drug: Cisplatin;   Drug: Gemcitabine;   Radiation: Intensity Modulated Radiation Therapy;   Behavioral: Quality of Life Questionnaires;   Genetic: Urine Collection for Molecular Analysis;   Genetic: Blood Collection for Molecular Analysis
32 Unknown  microRNA Expression in Renal Cell Carcinoma
Condition: Carcinoma, Renal Cell
Intervention:
33 Recruiting First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
Conditions: Locally Advanced and/or Metastatic Renal Cell Carcinoma;   Carcinoma, Renal Cell;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Pazopanib
34 Recruiting Hepatocellular Carcinoma Registry for Turkey (3K Trial)
Condition: Hepatocellular Carcinoma
Intervention: Other: No Intervention
35 Recruiting Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Conditions: Cancer of Head and Neck;   Head and Neck Cancer;   Neoplasms, Head and Neck;   Carcinoma, Squamous Cell of Head and Neck;   Squamous Cell Carcinoma of the Head and Neck;   Squamous Cell Carcinoma, Head and Neck
Interventions: Biological: MK-3475;   Procedure: Surgery;   Radiation: Intensity modulated radiation therapy;   Radiation: Image-guided radiation therapy;   Drug: Cisplatin
36 Recruiting Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma
Conditions: Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx
Interventions: Drug: vorinostat;   Drug: cisplatin;   Radiation: radiation therapy;   Procedure: Correlative Studies
37 Unknown  Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma
Condition: Carcinoma, Basal Cell
Intervention: Drug: Imiquimod 5% cream
38 Recruiting Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)
Conditions: Advanced Renal Cell Carcinoma;   Renal Cell Carcinoma;   Metastatic Renal Cell Carcinoma
Interventions: Drug: Standard Treatment;   Biological: AGS-003
39 Unknown  Proteomic Analysis of Human Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Intervention: Procedure: Operation
40 Recruiting Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)
Condition: Carcinoma, Renal Cell
Interventions: Drug: Pazopanib;   Device: DCE-MRI and Quantitative Doppler Ultrasound

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years